Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.90 USD
-0.22 (-10.38%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.90 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Brokerage Reports
Coherus BioSciences, Inc. [CHRS]
Reports for Purchase
Showing records 1 - 20 ( 68 total )
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Post 4Q; Adjusting Price Target to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q First Impressions: Moving Forward to Profitability in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Coherus Refines Its Focus Even Further; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
More Good News From Casdozo For Coherus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Heading Into 2024 Moving in the Right Direction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
On-Body Gives Coherus a Boost into the New Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Initial Data For Casdozo; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Lowered, But Foundation for 2024 Looks Solid; Price Target Down to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
That Was Fast... Udenyca On-Body BLA Refiled and Approval by Year-End is In Sight
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Perspectives on the Cost-Effectiveness of Treating wet AMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Revenues Resume Upward Trend; Adjusting PT to $20; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Coherus BioSciencesÂ’ Management; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Coherus Showcases Clinical Benefit of Toripalimab at ASCO 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Stirring the Pot as Coherus Sets Low Price for Yusimry on the Cusp of Market Formation for Humira Biosimilars
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Things Should Start to Turn; Adjusting PT to $24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D